Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE for liposarcoma, myxoid

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 30 May 2019: Trial registered, NCT03967223
  2. 31 Dec 2019: Trial started, NCT03967223

The trials

NCT03967223: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

State
Under way
Phase
Phase 2
People
103 taking part
Started
31 Dec 2019
Primary completion
1 Mar 2024
Arms
Substudy 1: lete-cel in previously untreated advanced (metastatic or unresectable) SS or MRCLS, Substudy 2: lete-cel in advanced (metastatic or unresectable) SS or MRCLS post anthracycline chemo
Results
None posted
  1. 30 May 2019: Trial registered
  2. 31 Dec 2019: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.